PMID- 24001317
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 67
IP  - 10
DP  - 2013 Oct
TI  - The effect of vildagliptin relative to sulphonylureas in Muslim patients with 
      type 2 diabetes fasting during Ramadan: the VIRTUE study.
PG  - 957-63
LID - 10.1111/ijcp.12243 [doi]
AB  - AIMS: To assess, in a real-world setting, the effect of vildagliptin compared 
      with sulphonylurea (SU) treatment on hypoglycaemia in Muslim patients with type 2 
      diabetes mellitus (T2DM) fasting during Ramadan. METHODS: This multinational, 
      non-interventional study, conducted in Asia and the Middle East, included Muslim 
      adult patients with T2DM who received treatment with vildagliptin or SU as add-on 
      to metformin or monotherapy. During a ~16-week observation period, data were 
      collected up to 6 weeks before and 6 weeks after Ramadan fasting. The primary 
      study objective was to compare the proportion of patients with >/= 1 hypoglycaemic 
      event (HE) during fasting. RESULTS: Of > 1300 patients enrolled in the study, 684 
      were treated with vildagliptin and 631 with SUs. Significantly fewer patients 
      experienced >/= 1 HE with vildagliptin compared with those receiving SUs (5.4% vs. 
      19.8%, respectively; p < 0.001); no vildagliptin-treated patients reported a 
      grade 2 HE, vs. 4 SU-treated patients (p = 0.053). Mean HbA1c changes from 
      baseline were vildagliptin: -0.24%, SUs: +0.02% (p < 0.001). Mean body weight 
      reductions from baseline were vildagliptin: -0.76 kg, SUs: -0.13 kg (p < 0.001). 
      A higher proportion of SU-treated patients experienced adverse events (AEs) 
      compared with vildagliptin (22.8% vs. 10.2%). This difference was driven by 
      hypoglycaemia as the most common AE. CONCLUSIONS: In this real-world study of 
      fasting Muslim patients with T2DM, vildagliptin was associated with significantly 
      fewer hypoglycaemic episodes compared with SU therapy. This outcome is 
      particularly meaningful when viewed in the context of good glycaemic and weight 
      control observed in vildagliptin-treated patients. Vildagliptin was well 
      tolerated in this patient population.
CI  - (c) 2013 The Authors. International Journal of Clinical Practice published by John 
      Wiley & Sons Ltd.
FAU - Al-Arouj, M
AU  - Al-Arouj M
AD  - Dasman Diabetes Institute, Kuwait, Kuwait.
FAU - Hassoun, A A K
AU  - Hassoun AA
FAU - Medlej, R
AU  - Medlej R
FAU - Pathan, M F
AU  - Pathan MF
FAU - Shaltout, I
AU  - Shaltout I
FAU - Chawla, M S
AU  - Chawla MS
FAU - Hristoskova, S
AU  - Hristoskova S
FAU - Ditommaso, S
AU  - Ditommaso S
FAU - Kadwa, M Y
AU  - Kadwa MY
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130903
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (Sulfonylurea Compounds)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
CIN - Int J Clin Pract. 2013 Oct;67(10):933-4. PMID: 24073969
MH  - Adamantane/*analogs & derivatives/therapeutic use
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*drug therapy/ethnology
MH  - Fasting/*physiology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*therapeutic use
MH  - *Islam
MH  - Male
MH  - Medication Adherence/ethnology
MH  - Middle Aged
MH  - Nitriles/*therapeutic use
MH  - Prospective Studies
MH  - Pyrrolidines/*therapeutic use
MH  - Sulfonylurea Compounds/*therapeutic use
MH  - Vildagliptin
MH  - Weight Loss/drug effects
PMC - PMC4230330
EDAT- 2013/09/05 06:00
MHDA- 2014/05/03 06:00
PMCR- 2014/11/13
CRDT- 2013/09/05 06:00
PHST- 2013/06/07 00:00 [received]
PHST- 2013/07/09 00:00 [accepted]
PHST- 2013/09/05 06:00 [entrez]
PHST- 2013/09/05 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
PHST- 2014/11/13 00:00 [pmc-release]
AID - 10.1111/ijcp.12243 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2013 Oct;67(10):957-63. doi: 10.1111/ijcp.12243. Epub 2013 Sep 
      3.